Drug Approval | November 21, 2025
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The move is expected to be crucial during health crises
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
The ten-day initiative, running from 10 to 21 November, brings together a team of highly skilled German doctors providing life-changing reconstructive surgeries at no cost
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Subscribe To Our Newsletter & Stay Updated
